Victory Capital Management Inc Rubius Therapeutics, Inc. Transaction History

Victory Capital Management Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 01, 2022	SELL	$0.79 - $5.98 $2.32 Million - $17.5 Million	-2,932,248 Closed	0 $0
Q1 2022 May 04, 2022	BUY	$4.25 - $10.4 $2.08 Million - $5.09 Million	489,248 Added 20.03%	2,932,248 $16.2 Million
Q4 2021 Feb 07, 2022	BUY	$9.68 - $17.74 $6.12 Million - $11.2 Million	631,892 Added 34.89%	2,443,000 $23.6 Million
Q3 2021 Nov 02, 2021	BUY	$17.6 - $25.91 $4.21 Million - $6.19 Million	238,921 Added 15.2%	1,811,108 $32.4 Million
Q2 2021 Aug 03, 2021	BUY	$22.26 - $28.43 $8.27 Million - $10.6 Million	371,370 Added 30.93%	1,572,187 $38.4 Million

Q1 2021 May 04, 2021	BUY	$8.02 - $32.01 $9.63 Million - $38.4 Million	1,200,817 New	1,200,817 $31.8 Million
Q2 2020 Aug 07, 2020	SELL	$4.01 - $6.88 $12,194 - $20,922	-3,041 Closed	0 $0
Q1 2020 May 04, 2020	SELL	$3.74 - $9.84 $5,015 - $13,195	-1,341 Reduced 30.6%	3,041 $14,000
Q4 2019 Feb 04, 2020	SELL	$7.23 - $14.12 $1,619 - $3,162	-224 Reduced 4.86%	4,382 $34,000
Q3 2019 Nov 12, 2019	BUY	$7.85 - $15.75 $36,157 - $72,544	4,606 New	4,606 $36,000

325

Ticker RUBY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 90,357,000
Description
Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers. It is also developing RTX-321 for the treatmen...

Get notified when there are updates to the investment portfolio of Victory Capital Management Inc, based on Form 13F filings with the SEC.

Stay updated on Victory Capital Management Inc with notifications on news.